Home/Pipeline/COM902

COM902

Solid Tumors

Phase 1/2ActiveNCT04354246

Key Facts

Indication

Solid Tumors

Phase

Phase 1/2

Status

Active

Company

Compugen

About Compugen

Compugen is a computational discovery-driven biotech focused on identifying and developing first-in-class cancer immunotherapies. Its core asset is the proprietary, AI/ML-powered Unigen™ platform, which integrates multi-omics data to predict novel immune checkpoints and therapeutic targets. The company has successfully translated its computational predictions into a clinical pipeline, with multiple programs in Phase 1/2 development. Its strategy is to advance these assets independently or through strategic partnerships to address significant unmet needs in oncology.

View full company profile

Therapeutic Areas

Oncology Immuno-oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed